• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Trending:
  • Kashmir
  • Elections
Friday, June 5, 2026

Daily Times

Your right to know

  • HOME
  • Latest
  • Iran-Israel war
  • Gilgit Baltistan Election
  • Pakistan
    • Balochistan
    • Gilgit Baltistan
    • Khyber Pakhtunkhwa
    • Punjab
    • Sindh
  • World
  • Editorials & Opinions
    • Editorials
    • Op-Eds
    • Commentary / Insight
    • Perspectives
    • Cartoons
    • Letters to the Editor
    • Featured
    • Blogs
      • Pakistan
      • World
      • Lifestyle
      • Culture
      • Sports
  • Business
  • Sports
  • E-PAPER
    • Lahore
    • Islamabad
    • Karachi

Web Desk

Pfizer CEO says people might need a third dose after 12 months

Published on: April 16, 2021 10:42 AM

pfizer

Pfizer CEO Albert Bourla said that it is highly likely that people will require a third vaccine shot within 12 months of being fully vaccinated.

Bourla said it is possible people will need to get vaccinated against the coronavirus annually.

“We need to see what would be the sequence, and for how often we need to do that, that remains to be seen,” Bourla told CNBC in an interview recorded on April 1.

“A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed,” he said, adding that variants will play a “key role.”

“It is extremely important to suppress the pool of people that can be susceptible to the virus,” he said.

At present, the researchers are not aware of how long the vaccine gives protection.

Pfizer said earlier this month that its Covid-19 vaccine was more than 91% effective at protecting against the coronavirus and more than 95% effective against severe disease up to six months after the second dose. Moderna’s vaccine, which uses technology similar to Pfizer’s, was also shown to be highly effective at six months.

Pfizer’s data was based on more than 12,000 vaccinated participants. However, researchers say more data is still needed to determine whether protection lasts after six months.

“It seems strong but there is some waning of that and no doubt the variants challenge,” he said.

“I think for planning purposes, planning purposes only, I think we should expect that we may have to boost.”

The Pfizer vaccine, developed in partnership with German firm BioNTech, currently plays a leading role in American and European vaccination campaigns.

The pharmaceutical giant announced in February that it was testing a third dose of its vaccine to better combat the emerging variants.

Filed Under: Top Stories, World Tagged With: pfizer, vaccine

Submit a Comment




Primary Sidebar




Latest News

Oil falls on hopes of broader peace after Lebanon, Israel halt fighting

Meat exports grow by 4.16%

SBP-held foreign reserves rise by $43m to $17.9bn

Gold prices up by Rs 1,523 per tola

Rupee strengthens against dollar

Pakistan

Bilawal seeks heavy public mandate to protect GB’s rights

PM directs pilot launch of automated tax collection system in Islamabad

Federal budget on June 10

PM hails special ties with Washington at event marking US 250th anniversary

FO rubbishes reports of Dar sharing Iran nuclear information with Rubio

More Posts from this Category

Business

Pakistan’s exports to US up by 1.70% to $5.12bn in 10 months

Pakistan, Tajikistan set $200 million trade target, deepen ties at 8th JCM

Services’ exports up by 17.68% to $8.26bn

OGDCL’s new wells deliver record oil, gas output in FY26

Buying returns as PSX gains nearly 1,000 points

More Posts from this Category

World

No sign of progress in US-Iran talks as Hezbollah rejects truce

Vast accelerates race to replace ISS

Gulf crisis drives India-Venezuela oil partnership

More Posts from this Category




Footer

Home
Lead Stories
Latest News
Editor’s Picks

Culture
Life & Style
Featured
Videos

Editorials
OP-EDS
Commentary
Advertise

Cartoons
Letters
Blogs
Privacy Policy

Contact
Company’s Financials
Investor Information
Terms & Conditions

Facebook
Twitter
Instagram
Youtube

© 2026 Daily Times. All rights reserved.

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.